Skip to content

Monthly research recap

Ketamine research: October 2026

What October 2026's 25 new studies found, synthesized from the papers below. All Ketamine research →

The synthesis

Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Ketamine, racemic ketamine, arketamine, R-ketamine, then ranked by relevance.

Research indexed in October 2026 on ketamine was broad and mostly early-stage: clinical work continued to support rapid antidepressant and anti-suicidal effects of low-dose ketamine/esketamine (including in adolescents receiving ECT and in repeated oral dosing for chronic suicidality), while mechanistic, animal, and real-world studies explored brain entropy, stress-axis and glial signaling, cost-effectiveness, and safety signals such as urinary symptoms and suicidality fluctuations. Results are directionally consistent for antidepressant benefit but come largely from small, open-label, interim, retrospective, or animal samples, so durability, blinding, and long-term safety remain unresolved.

Evidence by study

Direction is which way each study's own result points, not our rating of the study.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Study Design Sample size Direction Finding
Evaluating whether a therapeutic dose of ketamine exposure during adolescence influences adult vulnerability in rats to commonly abused drugs. 2026 controlled animal experiment No effect Seven days of adolescent ketamine (10 mg/kg) did not increase adult ethanol consumption or cocaine place preference in either sex.
Low-dose ketamine modulates brain entropy in treatment-resistant depression: Results from two neuroimaging clinical trials. 2026 secondary analysis of two RCTs Supports Low-dose ketamine increased brain entropy from baseline to day 3 in frontolimbic, cerebellar, and neuromodulatory regions, which the authors suggest may relate to rapid antidepressant effects.
Esketamine-Associated Lower Urinary Tract Symptoms Suggestive of Bladder Overactivity in Treatment-Resistant Depression: A Case Report 2026 case study 1 Opposes A patient developed urinary urgency and pelvic discomfort after starting intranasal esketamine, with symptoms resolving after dosing was spaced out.
Treatment Response Following Repeated Low-Dose Oral Ketamine in Adults with Chronic Suicidality 2026 open-label pilot study (thesis) 32 Supports Weekly low-dose oral ketamine for six weeks was associated with reduced suicidal ideation in 69% of participants and tolerable side effects, with early response predicting later response.
Effects of Social Isolation on the Behavior of Wistar Rats Subjected to a Ketamine-Induced Model of Schizophrenia 2026 experimental animal study 144 Mixed Ketamine increased locomotion and reduced rearing (more so in females), while social isolation produced separate, largely independent behavioral effects with no ketamine-by-isolation interaction.
Ketamine Versus Electroconvulsive Therapy for Nonpsychotic Treatment-Resistant Depression: A Cost-Effectiveness Analysis 2026 cost-effectiveness analysis Supports In a 29-week model, racemic ketamine yielded slightly more QALYs (0.024) at lower health-care and societal costs than ECT and was cost-effective in nearly all sensitivity analyses.
A ketamine derivative exerts enhanced antidepressant effects via adenosine signaling. 2026 preclinical animal study Supports A single 2 mg/kg dose of the ketamine derivative 3C-DCK produced antidepressant-like effects lasting up to 72 hours, longer than ketamine, without hyperlocomotion or ataxia, attributed to adenosine signaling.
Targeting NMDAR2A in microglia: esketamine suppresses M1 polarization in BV2 cells. 2026 in vitro cell study Supports Esketamine suppressed LPS-induced M1 microglial polarization and pro-inflammatory cytokine expression via NMDAR2A, mTOR, and BDNF-TrkB signaling.
Subanesthetic-dose esketamine-assisted electroconvulsive therapy for suicidal ideation in adolescents with major depressive disorder: Interim trial results 2026 randomized double-blind controlled trial (interim) 113 Supports Adjunctive esketamine (0.25 mg/kg) during ECT produced faster reduction in suicidal ideation and higher response rates (76.8% vs 57.9%) than saline, with similar remission rates and no short-term cognitive decline.
Integrating multi-receptor and neuron–glia mechanisms of ketamine's antidepressant action: a convergence framework for understanding efficacy 2026 review Unclear Argues that ketamine's antidepressant efficacy likely arises from convergent multi-receptor and neuron-glia actions, and that many components of this model remain hypothetical.
What is the efficacy of low-dose ketamine for treating depression and other mental health conditions? 2026 review Supports Reports moderate efficacy of ketamine as a rapid-acting treatment for treatment-resistant and bipolar depression, with monitoring needed given limited long-term safety data.
Chronic High‐Dose Ketamine Fails to Induce a Cystitis‐Like Phenotype in Mice Despite High Urinary Metabolite Levels 2026 controlled animal experiment 40 No effect Twelve weeks of high-dose ketamine (100 mg/kg) produced high urinary and plasma metabolite levels but no cystitis-like voiding, sensory, or histopathological changes versus saline.
Suicidality during intranasal (es)ketamine treatment: A retrospective cohort study. 2026 retrospective cohort study 80 Mixed Mean suicidality decreased modestly, upward and downward transitions occurred at similar rates, but a minority showed transient or sustained worsening and one suicide occurred.
Neural correlates of ketamine-induced dilation of temporal expectation 2026 observational animal study 2 Supports Subanesthetic ketamine caused dose-dependent dilation of time estimation, paralleled by flattened anticipatory ramping and rotated population activity in parietal area LIP.
Quality of Life in Patients with Treatment-Resistant Depression Treated with Intranasal Esketamine as Add-On Therapy to an SSRI—A Prospective, Comparative Study in Real-World Clinical Practice 2026 prospective observational cohort 60 Supports Both groups improved in quality of life and depressive severity, with larger absolute changes in the esketamine add-on group, though the authors caution against causal interpretation.
Depression: Ketamine quiets an unruly habenula. 2026 commentary Supports Describes evidence that the ~24-hour window of ketamine's antidepressant effects coincides with reduced habenula activation and reduced aversive learning in healthy subjects.
Subanesthetic ketamine modulates region-specific neural and endocrine responses to acute stress in rats. 2026 controlled experimental animal study Supports Subanesthetic ketamine (15 mg/kg) reduced immobility and attenuated stress-induced corticosterone increases, with region-specific and context-dependent c-Fos changes.
Feeling safe: an empirical-ethical analysis of vulnerability in (es)ketamine treatment 2026 qualitative study 24 Unclear Argues that feeling safe in (es)ketamine treatment is relationally created through therapeutic presence, grounding, and transitional support, and that patient and clinician models of the treatment can diverge.
Peripartum Esketamine: A Narrative Review of Analgesia, Postpartum Depressive Symptoms, Sleep-Related Outcomes, and Safety. 2026 narrative review Mixed Evidence is most consistent for short-term analgesic benefit of peripartum esketamine, with some trials suggesting reduced early postpartum depressive symptoms, but routine prophylactic use is not supported and long-term safety data are insufficient.
Ketamine administration reduced conditioned defensive behaviour and upregulated protein expression associated with neuroplasticity in a planarian model of aversive memory reactivation. 2026 preclinical experimental study 15 Supports 10 μM ketamine reduced defensive behaviors during aversive memory reactivation and was associated with proteomic enrichment of neuroplasticity-related pathways.
Esketamine alleviates the pain-depression dyad: insights from exploratory transcriptomic profiling and Wnt4-associated molecular alterations within the anterior cingulate cortex 2026 experimental animal study Supports A single 15 mg/kg esketamine dose alleviated pain hypersensitivity, behavioral despair, and anhedonia, associated with Wnt4-related and GSK3β-mTOR signaling changes in the anterior cingulate cortex.
Real-world clinical outcomes under intravenous and subcutaneous esketamine protocols for treatment-resistant depression: a multicenter, retrospective study 2026 retrospective chart review 72 No effect BDI-II response favored IV over SC esketamine after six sessions but was not statistically significant (p=0.059), and endpoint response did not differ; dissociation was more frequent with IV.
Adjunctive ketamine for affective symptoms, craving, and relapse prevention in opioid use disorder: protocol for a randomised, double-blind, placebo-controlled clinical trial 2026 clinical trial protocol Unclear Describes a planned double-blind placebo-controlled trial of six IV ketamine infusions (0.5 mg/kg) targeting depressive symptoms and relapse-related outcomes in opioid use disorder.
French psychiatric caregivers' perceptions of psychedelics: A national survey. 2026 cross-sectional survey 298 Mixed 53% rated the therapeutic benefit-risk ratio of psychedelics favorably while 61% rated recreational use as dangerous, and favorable therapeutic views were associated with clinical practice with ketamine.
Longitudinal peripheral DNA methylation remodeling following ketamine-assisted psychotherapy in major depressive disorder 2026 longitudinal observational study 10 Supports Depressive symptoms improved markedly after ketamine-assisted psychotherapy, alongside exploratory DNA methylation changes enriched for NOTCH1-related pathways, which the authors say do not establish causality.

Points of agreement

  • Multiple clinical reports support rapid antidepressant and anti-suicidal effects of low-dose ketamine or esketamine, including in treatment-resistant depression and in adolescents receiving ECT.
  • Animal and in vitro work consistently points to neuroplastic, glial, and stress-axis mechanisms underlying ketamine's effects.
  • Several sources note that long-term safety and durability data remain limited, warranting monitoring and cautious patient selection.

Conflicts

  • Urinary safety signals conflict: a case report links intranasal esketamine to bladder-overactivity symptoms, while a chronic high-dose mouse study found no cystitis-like phenotype.
  • Suicidality outcomes differ in emphasis: one open-label trial reports substantial ideation reduction, while a retrospective cohort finds modest mean improvement with frequent upward and downward transitions and some worsening.
  • Real-world comparative data are equivocal: one cohort shows larger quality-of-life gains with esketamine add-on, while a retrospective comparison of IV versus SC routes finds no significant response difference.

Gaps

  • Long-term durability and safety of repeated ketamine/esketamine dosing are largely unestablished.
  • Many clinical findings come from small, open-label, interim, retrospective, or non-randomized samples with confounding risk.
  • Blinding integrity and placebo control are rarely addressed in the clinical reports.
  • Pediatric, peripartum, and opioid-use-disorder populations remain understudied, with some work still at protocol stage.
  • Mechanistic models (multi-receptor, adenosine, glial) remain largely preclinical and require in vivo verification.
Browse these studies in the library